Effects of Biological Therapies on Molecular Features of Rheumatoid Arthritis
Authors:
- Chary Lopez-PedreraCLChary Lopez-Pedrera
- Nuria BarbarrojaNBNuria Barbarroja
- Alejandra M. Patiño-TrivesAPAlejandra M. Patiño-Trives
- Maria Luque-TévarMLMaria Luque-Tévar
- Eduardo Collantes-EstevezECEduardo Collantes-Estevez
- Alejandro Escudero-ContrerasAEAlejandro Escudero-Contreras
- Carlos Pérez-SánchezCPCarlos Pérez-Sánchez
Open Access
- 28 November 2020
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (23) , 9067
Abstract
Rheumatoid arthritis (RA) is an autoimmune and chronic inflammatory disease primarily affecting the joints, and closely related to specific autoantibodies that mostly target modified self-epitopes. Relevant findings in the field of RA pathogenesis have been described. In particular, new insights come from studies on synovial fibroblasts and cells belonging to the innate and adaptive immune system, which documented the aberrant production of inflammatory mediators, oxidative stress and NETosis, along with relevant alterations of the genome and on the regulatory epigenetic mechanisms. In recent years, the advances in the understanding of RA pathogenesis by identifying key cells and cytokines allowed the development of new targeted disease-modifying antirheumatic drugs (DMARDs). These drugs considerably improved treatment outcomes for the majority of patients. Moreover, numerous studies demonstrated that the pharmacological therapy with biologic DMARDs (bDMARDs) promotes, in parallel to their clinical efficacy, significant improvement in all these altered molecular mechanisms. Thus, continuous updating of the knowledge of molecular processes associated with the pathogenesis of RA, and on the specific effects of bDMARDs in the correction of their dysregulation, are essential in the early and correct approach to the treatment of this complex autoimmune disorder. The present review details basic mechanisms related to the physiopathology of RA, along with the core mechanisms of response to bDMARDs.Keywords
Funding Information
- Instituto de Salud Carlos III (PI18/0837, RD16/0012/0015)
- Consejería de Salud, Junta de Andalucía (PI-0285-2017)
This publication has 161 references indexed in Scilit:
- Pretreatment synovial transcriptional profile is associated with early and late clinical response in rheumatoid arthritis patients treated with rituximabAnnals of the Rheumatic Diseases, 2012
- Serum level of oxidative stress marker is dramatically low in patients with rheumatoid arthritis treated with tocilizumabRheumatology International, 2011
- MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritisProceedings of the National Academy of Sciences, 2011
- Monocyte migration to the synovium in rheumatoid arthritis patients treated with adalimumabAnnals of the Rheumatic Diseases, 2011
- Neutrophils: game changers in glomerulonephritis?Trends in Molecular Medicine, 2010
- Fibroblast‐like synoviocytes: key effector cells in rheumatoid arthritisImmunological Reviews, 2009
- Fibroblasts from different sites may promote or inhibit recruitment of flowing lymphocytes by endothelial cellsEuropean Journal of Immunology, 2009
- Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapyModern Rheumatology, 2008
- Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systemsNature Reviews Immunology, 2007
- Anti–TNF-α therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-βJournal of Experimental Medicine, 2007